MARKET

OGEN

OGEN

Oragenics
AMEX
0.2800
-0.0072
-2.51%
After Hours: 0.2662 -0.0138 -4.93% 19:26 03/14 EDT
OPEN
0.2777
PREV CLOSE
0.2872
HIGH
0.3000
LOW
0.2777
VOLUME
419.72K
TURNOVER
--
52 WEEK HIGH
3.430
52 WEEK LOW
0.2500
MARKET CAP
3.84M
P/E (TTM)
-0.0430
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OGEN last week (0303-0307)?
Weekly Report · 4d ago
Oragenics submits IB for Phase II clinical trial of ONP-002 in mTBI
TipRanks · 03/06 14:35
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Barchart · 03/06 08:30
Weekly Report: what happened at OGEN last week (0224-0228)?
Weekly Report · 03/03 09:37
Oragenics CMO to present at Emergencies in Medicine Conference
TipRanks · 02/25 14:03
Press Release: Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
Dow Jones · 02/24 13:30
Weekly Report: what happened at OGEN last week (0217-0221)?
Weekly Report · 02/24 09:37
Weekly Report: what happened at OGEN last week (0210-0214)?
Weekly Report · 02/17 09:36
More
About OGEN
More
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Recently
Symbol
Price
%Change

Webull offers Oragenics Inc stock information, including AMEX: OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.